Vyxeos
Sponsors
Children's Hospital Medical Center, Cincinnati, University of Birmingham, University of California, San Diego, H. Lee Moffitt Cancer Center and Research Institute, Shaare Zedek Medical Center
Conditions
AMLAML, AdultAcute Myeloid LeukaemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia, AdultHigh-risk Myelodysplastic SyndromeLeukemia
Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
RecruitingNCT03826992
Start: 2018-12-27End: 2028-01-01Target: 21Updated: 2026-02-18
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
RecruitingNCT05024552
Start: 2022-02-25End: 2027-03-31Target: 22Updated: 2025-12-05
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RecruitingNCT05558124
Start: 2023-02-16End: 2027-04-01Target: 18Updated: 2026-02-27
Phase 2
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
Active, not recruitingNCT04217278
Start: 2020-01-27End: 2026-05-01Updated: 2026-05-05
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
TerminatedNCT04425655
Start: 2020-08-05End: 2022-07-01Updated: 2022-09-22
Vyxeos for Induction of Low- or Intermediate-risk.
Active, not recruitingNCT05599360
Start: 2022-08-07End: 2028-09-07Updated: 2026-09-03